Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxide adsorbed allergoid preparation of 6-Grasses in patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma.

Trial Profile

A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxide adsorbed allergoid preparation of 6-Grasses in patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Rhinoconjunctivitis
  • Focus Adverse reactions
  • Acronyms ONSeT
  • Sponsors Allergopharma
  • Most Recent Events

    • 06 Oct 2018 This trial has been completed in Germany .
    • 25 Jul 2018 This trial has been completed in Poland (end date: 2018-07-03).
    • 07 Jul 2018 This trial has been completed in Spain (end date: 2018-07-03)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top